Risk factors

Hancock Whitney added risks regarding credit card caps, securities portfolio losses, and sustainability expectations.

The filing lacks prior year risk data to compare changes.

No new, removed, or reworded risks were provided.

Bitcoin price volatility is highlighted with trailing ten-year volatility ticking down slightly from 66% to 65%.

Regulatory scrutiny over prediction markets and cryptocurrency assets poses new legal and operational hurdles for the company.

Federal government revenue contribution declined from 54% to 43% while commercial client revenue increased to 33%. Federal risk disclosures removed references to the DOGE advisory commission.

Portfolio optimization and divestitures, including strategic alternatives for the Food Ingredients segment, carry significant execution and separation risks.

Banking-industry failures now emphasize depositor confidence, regulatory scrutiny, deposit competition and liquidity risks.

Indie Semiconductor faces major strategic shifts centered around the pending Wuxi divestiture to United Faith and ongoing restructuring plans. Debt levels slightly decreased while compliance and trade tariff risks remain prominent operational focus areas.

InfuSystem added new risks regarding healthcare advisory panel changes and state-level health privacy compliance complexity. Net operating loss carryforwards decreased from $14.4 million to $5.8 million, all of which now have indefinite lives. Third-party payer contract non-renewal risks were expanded.

Tariffs and a Section 232 investigation could raise imported-material costs and disrupt supply of oxygen concentrator components.

Proposed EMEA packaging spin-off introduces execution, cost, regulatory-approval and customer-disruption risk.